Contact Radiotherapy for Rectal Cancer

The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).

Trial Details

NCT ID
NCT06501053
Phase
NA
Sponsor
Alexander Valdman
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Radiotherapy
  • Short-course radiotherapy
  • Contact x-ray brachytherapy
  • Chemotherapy
Locations (sample)
  • Stockholm, Solna, Sweden|59.32938,18.06871
  • Uppsala, Sweden|59.85882,17.63889

Key Eligibility Criteria

  • Adenocarcinoma of the rectum classified as:
  • cT1-cT3ab, \< 5 cm largest diameter and \< ½ circumference (MRI staging), N0-N1 (\<= 3 nodes \< 8mm diameter), M0
  • Performance status (ECOG) 0-1
  • Operable patient

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →